Heron Therapeutics, Inc.

NASDAQ:HRTX

Biotechnology

Healthcare
$0.26 +3.74%

+$0.01 today

Market cap
$50.25M
Beta
1.57
P/E (TTM)
-2.5
EPS (TTM)
-$0.16
52W Low $0.38High $2.30

Volume 3.60M

Average 2.90M

Income Statement

Follow revenue through to earnings.

Revenue

$154.90M

FY 2025 · Annual

+7.4% YoY

Operating Income

-$2.54M

FY 2025 · Annual

Net Income

-$20.20M

FY 2025 · Annual

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue86.35M107.67M127.04M144.29M154.9M
Cost of Revenue46.02M54.87M65.11M38.65M41.35M
Gross Profit40.33M52.8M61.94M105.64M113.56M
Gross Margin46.7%49.0%48.8%73.2%73.3%
Research & Development130.82M82.7M39.13M16.68M12.43M
Selling, General & Admin127.33M144.75M119.82M100.48M103.67M
Operating Expenses258.15M227.46M172.55M117.17M116.1M
Depreciation & Amortization3.02M2.89M2.9M2.49M2.31M
EBITDA(215.25M)(176.66M)(103.79M)(5.06M)(17.88M)
EBITDA Margin-249.3%-164.1%-81.7%-3.5%-11.5%
Operating Income(217.83M)(174.66M)(110.62M)(11.53M)(2.54M)
Operating Margin-252.3%-162.2%-87.1%-8.0%-1.6%
Interest Income433K1.64M3.36M3.55M0
Interest Expense2.41M2.47M3.87M6.03M0
Other Income / Expenses(2.86M)(7.37M)56K(2.05M)(17.66M)
Income Before Tax(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Pre-Tax Margin-255.6%-169.1%-87.0%-9.4%-13.0%
Income Tax Expense00000
Net Income(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Net Margin-255.6%-169.1%-87.0%-9.4%-13.0%
EPS (Basic)(2.24)(1.67)(0.80)(0.09)(0.12)
EPS (Diluted)(2.24)(1.67)(0.80)(0.09)(0.12)
Weighted Avg Shares98.47M109M138.14M152.45M166.71M
Weighted Avg Shares (Diluted)98.47M109M138.14M152.45M166.71M

HRTX Earnings Waterfall · TTM

NASDAQ:HRTX · Revenue to Net Income

Key Ratios

EPS$-0.18
Gross Margin70.9%
Net Margin-20.7%
P/E Ratio-14.9
P/S Ratio6.0

Analysis

$150.7M of revenue converted into -$30.9M of net income for the selected period. Gross margin is 70.9% and net margin is -20.7%, showing how much revenue survives after costs and taxes. EPS is $-0.18, tying the income statement back to per-share earnings.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
4Statement of changes in beneficial ownershipNov 10, 2026
8-KCurrent reportNov 9, 2026
8-KCurrent reportNov 9, 2026
DEFA14ADEFA14A filingNov 9, 2026
DEFA14ADEFA14A filingNov 9, 2026

How much revenue does HRTX generate?

Heron Therapeutics, Inc. (HRTX) reported $154.90M of revenue in fiscal 2025.

Is HRTX profitable?

Heron Therapeutics, Inc. (HRTX) reported -$20.20M of net income, with a net margin of -13.0%.